REFERENCES
United States Food and Drug Administration. How drugs are developed and approved-types of applications. 2010. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/default.htm. Accessed 2013
United States Pharmacopeia and National Formulary (USP 36-1159NF 31). Rockville, MD: United States Pharmacopeia Convention; 2013.
United States Government. Title 21—Food and Drugs Section 330.1: general conditions for general recognition as safe, effective and not misbranded. Code of Federal Regulations (annual edition); 2011.
United States Pharmacopeial Convention. Key Issue: Monograph Modernization. 2012. Available from: http://www.usp.org/usp-nf/key-issues/monograph-modernization. Accessed 2013
United States Pharmacopeial Convention. Pharmacopeial Forum (PF). Available from: http://www.usp.org/usp-nf/pharmacopeial-forum. Accessed 2013
United States Pharmacopeial Convention. White Paper: Modernization of Organic Impurities Testing in USP Drug Product Monographs. 2013 [cited 2013]; Available from: http://www.usp.org/usp-nf/key-issues/monograph-modernization/organic-impurities-drug-monographs/white-paper-modernization-organic-impurities.
United States Pharmacopeial Convention. Over-the-Counter (OTC) Drug Substances and Drug Products Workshop. 2011. Available from: http://www.usp.org/meetings-courses/workshops/over-counter-otc-drug-substances-and-drug-products-workshop. Accessed 2013
Argentine M, Owens P, Olsen B. Strategies for the investigation and control of process-related impurities in drug substances. Adv Drug Deliv Rev. 2007;59(1):12–28.
Pilaniya K, Chandrawanshi H, Pilaniya U, Manchandani P, Jain P, Singh N. Recent trends in the impurity profile of pharmaceuticals. J Adv Pharm Technol Res. 2010;1(3):302–10.
Li Y, Liu D, Yang S, Sudini R, McGuire M, Bhanushali D, et al. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping. J Pharm Biomed Anal. 2010;52(4):493–507.
Teasdale A, Elder D, Chang S, Wang S, Thompson R, Benz N, et al. Risk assessment of genotoxic impurities in new chemical entities: strategies to demonstrate control. Org Process Res Dev. 2013;17(2):221–30.
Chan Li Q, Qiu F, Cohen K, Tougas T, Li J, McCaffrey J, et al. Best practices for drug substance stress and stability studies during early-stage development part I—conducting drug substance solid stress to support phase Ia clinical trials. J Pharm Innov. 2012;7:214–24.
Chan Li Q, Qiu F, Cohen K, Tougas T, Li J, McCaffrey J, et al. Best practices for drug substance stress and stability studies during early-stage development part II—conducting abbreviated long-term and accelerated stability testing on the first clinical drug substance batch to confirm and adjust the drug substance retest period/powder for oral solution shelf life. J Pharm Innov. 2013;8:56–65.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7: Draft Consensus Guideline. ICH Harmonized Tripartite Guidelines; 2013.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for Industry Q3B Impurities in New Drug Products (Revision 2). ICH Harmonized Tripartite Guidelines; 2006.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for Industry Q3A Impurities in New Drug Substances (Revision 2). ICH Harmonized Tripartite Guidelines; 2008.
United States Pharmacopeial Convention. General Chapters. Available from: http://www.usp.org/usp-nf/harmonization/general-chapters. Accessed 2013
United States Pharmacopeial Convention. Monographs. [cited 2013]; Available from: http://www.usp.org/usp-nf/harmonization/monographs 2012.
United States Pharmacopeial Convention. USP Reference Standards. Available from: http://www.usp.org/store/products-services/reference-standards. Accessed 2013
21 CFR 314 Applications for FDA Approval to Market a New Drug,” [Content and Format of an Abbreviated New Drug Application, Sec. 314.94 (9)].
Food and Drug Administration (FDA). Guidance for Industry, ANDAs: impurities in Drug Substances (R1) 2009.
Food and Drug Administration (FDA). Guidance for Industry: ANDAs: Impurities in Drug Products 2010.
Crowley P, Martini LG. Drug-excipient interactions. Pharm Tech. 2001.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for the Industry Q3C: Impurities: Residual Solvents. ICH Harmonized Tripartite GuidelinesJune 1997. p. 1–2.
United States Pharmacopeia and National Formulary (USP 35-NF 30). Rockville, MD: United States Pharmacopeia Convention; 2012. p. 5089.
Food and Drug Administration (FDA). OPS, MAPP 5015.8 Acceptance criteria for residual solvents. 2009.
Food and Drug Administration (FDA). Questions and Answers on Residual Solvents in ANDAs: Guidance, Compliance, & Regulatory Information [Internet]. 2008. Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CenterforDrugEvaluationandResearch/ucm119607.pdf.
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the Specification Limits for Residues of Metal Catalysts or Metal Reagents. Doc Ref EMEA/CHMP/SWP/4446/2000 February 2008. p. 1–2.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for the Industry:Q8: Pharmaceutical Development (R2). ICH Harmonized Tripartite Guidelines 2009. pp. 1–2.
Committee for Medicinal Products for Human Use (CHMP). Guideline on the Limits of Genotoxic Impurities. In: European Medicines Agency (EMEA), editor. London UK 2006.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for industry-genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (Draft Guidance). ICH Harmonized Tripartite Guidelines 2008.
Snodin DJ, McCrossen SD. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment. Regul Toxicol Pharmacol. 2012;63(2):298–312.
Olsen BA, Baertschi SW. Strategies for investigation and control of process and degradation-related impurities. In: Ahuja S, Alsante K, editors. Handbook of isolation and characterization of impurities in pharmaceuticals. San Diego: Academic; 2003. p. 89–117.
Argentine MD, Owens PK, Olsen BA. Strategies for the investigation and control of process-related impurities in drug substances. Adv Drug Deliv Rev. 2007;59(1):12–28.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidance for the Industry Q3D: Impurities: Guideline for Metal Impurities (Final Concept Paper). ICH Harmonized Tripartite Guidelines; 2009. p. 1–2.
United States Pharmacopeial Convention. Key Issue: Elemental Impurities. USP-NF Key Issues (http://wwwusporg/usp-nf/key-issues/elemental-impurities) [Internet]. 2013. Available from: http://www.usp.org/usp-nf/key-issues/elemental-impurities.
International Pharmaceutical Excipients Council of the Americas. Press Release-Coalition for Rational Implementation of the USP Elemental Impurities Requirements. IPEC-Americas Insider [Internet]. Available from: http://ipecamericas.org/Press-release-coalition. 2012.
Snodin DJ, Elder DP. Genotoxic Impurities Part 1: General Overview. Pharmaceutical Outsourcing [Internet]. 2012. Available from: http://www.pharmoutsourcing.com/Featured-Articles/113769-Genotoxic-Impurities-Part-1-General-Overview/.
Stress Testing: Predictive or Overkill? Informa Life Sciences 5th Annual Conference on Forced Degradation; London, UK; 2011.
Reid DL, Calvitt CJ, Zell MT, Miller KG, Kingsmill CA. Early prediction of pharmaceutical oxidation pathways by computational chemistry and forced degradation. Pharm Res. 2004;21(9):1708–17.
Boccardi G. Autoxidation of drugs: prediction of degradation impurities from results of reaction with radical chain initiators. Farmaco. 1994;49(6):431–5.
Yao J, Dokuru DK, Noestheden M, Park SS, Kerwin BA, Jona J, et al. A quantitative kinetic study of polysorbate autoxidation: the role of unsaturated fatty acid ester substituents. Pharm Res. 2009;26(10):2303–13.
Baertschi SW, Jansen PJ, Alsante KM. Stress Testing: A Predictive Tool (Chapter 2). In: Baertschi SW, Alsante KM, Reed RA, editors. Pharmaceutical stress testing: predicting drug degradation: Informa Life Sciences; 2011. pp. 10–48.
Watkins MA, Pitzenberger S, Harmon PA. Direct evidence of 2-cyano-2-propoxy radical activity during AIBN-based oxidative stress testing in acetonitrile-water solvent systems. J Pharm Sci. 2013;102(5):1554–68.
Niu QJ, Mendenhall GD. Yields of singlet molecular oxygen from peroxyl radical termination. J Am Chem Soc. 1992;114(1):165–72.
Brustugun J, Tonnesen HH, Klem W, Kjonniksen I. Photodestabilization of epinephrine by sodium metabisulfite. PDA J Pharm Sci Technol. 2000;54(2):136–43.
Seburg RA, Ballard JM, Hwang TL, Sullivan CM. Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. J Pharm Biomed Anal. 2006;42(4):411–22.
Goldstein S, Meyerstein D, Czapski G. The Fenton reagents. Free Radic Biol Med. 1993;15(4):435–45.
Baertschi S, Draper J, Jansen P, Smith W, editors. Oxidative susceptibility testing: rapid, comprehensive screening techniques. 3rd Annual Forced Degradation Conference Institute for International Research, Short Hills, NJ. 2006.
Wagner T, Martin W, Lipp R, Iffert B, Michel H, Westermann J, et al., inventors. Antioxidant in manufacture of prostane pharmaceuticals. 1999.
United States Pharmacopeia and National Formulary (USP 27-NF 22): Monograph 27 “Containers for Dispensing Capsules and Tablets”. 22nd ed. Rockville, MD: United States Pharmacopeial Convention; 2004.
Fasani E, Albini A. Photostability Stress Testing (Chapter 7). In: Baertschi SW, Alsante KM, Reed RA, editors. Pharmaceutical Stress Testing: Predicting Drug Degradation (Drugs and the Pharmaceutical (Sciences). Second Edition ed: Informa Life Sciences; 2011. p. 192–217.
Clapham D, Templeton A, Klein L, Kleinman MH. Practical aspects of conducting photostability stress testing (Chapter 8). In: Baertschi SW, Alsante KM, Reed RA, editors. Pharmaceutical Stress Testing: Predicting Drug Degradation (Drugs and the Pharmaceutical (Sciences). Second Edition ed: Informa Life Sciences; 2011. p. 218–32.
Thatcher SR, Mansfield RK, Miller RB, Davis CW, Baertschi SW. Pharmaceutical photostability: a technical and practical interpretation of the ICH guideline and its application to pharmaceutical stability: part I. Pharm Tech. 2001;25(3):98–110.
Thatcher SR, Mansfield RK, Miller RB, Davis CW, Baertschi SW. Pharmaceutical photostability: a technical and practical interpretation of the ICH guideline and its application to pharmaceutical stability: part II. Pharm Tech. 2001;25(4):50–62.
Baertschi SW, Alsante KM, Tonnesen HH. A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): recommendation for revision. J Pharm Sci. 2010;99(7):2934–40.
Baertschi S, Clapham D, Foti C, Jansen P, Kristensen S, Reed R, et al. Implications of in use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products Part I. Drug Products Administered by Injection. J Pharm Sci. 2013;(in press).
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Stability Testing: Photostability Testing of New Drug Substances and Products Q1B (Step 4 Version). ICH Harmonized Tripartite Guidelines; 1996.
Kristensen S. Photostability of Parenteral Products (Chapter 14). In: Tonnesen H, editor. Photostability of Drugs and Drug Formulations. Second ed. Boca Raton, Florida: CRC Press; 2004. p. 448.
Brustugun J, Tonnesen HH, Edge R, Navaratnam S. Formation and reactivity of free radicals in 5-hydroxymethyl-2-furaldehyde—the effect on isoprenaline photostability. J Photochem Photobiol B. 2005;79(2):109–19. Epub 2005 Jan 26.
Reed RA, Harmon P, Manas D, Wasylaschuk W, Galli C, Biddell R, et al. The role of excipients and package components in the photostability of liquid formulations. PDA J Pharm Sci Technol. 2003;57(5):351–68.
Lu Y, Bowen WE, Reed RA. Titanium Dioxide Induced Photo-oxidation in Pharmaceutical Formulation Solutions. In: The Photostability of Drugs Interest Group, editor. 5th International Conference on Photostability of Drugs and Drug Products (PPS'04); London, UK; 2004.
Paul IC, Curtin DY. Thermally induced organic reactions in the solid state. Acc Chem Res. 1973;6(7):217–25.
Carstensen JT. Solid pharmaceutics: mechanical properties and rate phenomena. New York: Academic; 1980. 259 p.
Morawetz H. Reactivity of organic crystals. Science. 1966;152(3723):705–11.
Guerrieri PP, Smith DT, Taylor LS. Phase behavior of ranitidine HCl in the presence of degradants and atmospheric moisture–impact on chemical stability. Langmuir. 2008;24(8):3850–6.
Shalaev EY, Zografi G. How does residual water affect the solid-state degradation of drugs in the amorphous state? J Pharm Sci. 1996;85(11):1137–41.
Schmidt GMJ. Photodimerization in the solid state. Pure Appl Chem. 1971;27:647–78.
Kearsley SK. The prediction of chemical reactivity within organic crystals using geometric criteria. In: Desiraju GR, editor. Organic solid-state chemistry. New York: Elsevier; 1987. p. 69–115.
Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.
Govindarajan R, Zinchuk A, Hancock B, Shalaev E, Suryanarayanan R. Ionization states in the microenvironment of solid dosage forms: effect of formulation variables and processing. Pharm Res. 2006;23(10):2454–68.
Stephenson GA, Groleau EG, Kleemann RL, Xu W, Rigsbee DR. Formation of isomorphic desolvates: creating a molecular vacuum. J Pharm Sci. 1998;87(5):536–42.
Byrn SR, Sutton PA, Tobias B, Frye J, Main P. Crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tert-butylacetate. J Am Chem Soc. 1988;110(5):1609–14.
Merritt JM, Viswanath SK, Stephenson GA. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation. Pharm Res. 2013;30(1):203–17.
Dotterer SK, Forbes RA, Hammill CL. Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation. J Pharm Biomed Anal. 2011;54(5):987–94.
Yang S, Caltabiano A, Wu L, Shen J, Chen J, Kord A, et al. Identification and control of metal-chelating chromatographic artifacts in the analysis of a malonohydrazide derivative drug compound. J Pharm Biomed Anal. 2010;53(3):371–5.
Murahashi S, Komiya N, Hayashi Y, Kumano T. Copper complexes for catalytic, aerobic oxidation of hydrocarbon. Pure Appl Chem. 2001;73(2):311–4.
Petrier C, Jeunet A, Luche JL, Reverdy G. Unexpected frequency effects on the rate of oxidative processes induced by ultrasound. J Am Chem Soc. 1992;114(8):3148–50.
Li M, Ahuja ES, Watkins DM. LC-MS and NMR determination of a dichloromethane artifact adduct, cyproheptadine chloromethochloride. J Pharm Biomed Anal. 2003;31(1):29–38.
Skibic MJ, King LA, Khan M, Fox PJ, Winger BE, Baertschi SW. Artifactual formylation of the secondary amine of duloxetine hydrochloride by acetonitrile in the presence of titanium dioxide: implications for HPLC method development. J Pharm Biomed Anal. 2010;53(3):432–9.
Lin M, Li M, Rustum A. Identification of an unknown extraneous contaminant in pharmaceutical product analysis. J Pharm Biomed Anal. 2007;45(5):747–55.
Orford C, Webb ML, Cattanach KH, Cottee FH, Escott RE, Pitfield ID, et al. An analytical and structural study of the photostability of some leukotriene B4 antagonists. In: Albini A, Fasani E, editors. Drugs: photochemistry and photostability. Cornwall, UK: Royal Society of Chemistry; 1998. p. 182–93.
Acknowledgments
The organizing committee would like to thank all the speakers for sharing their work at this conference and through this publication.
Disclaimer
The views and opinions in this article are only those of the authors and do not necessarily reflect the views or policies of the companies, organizations or agencies cited herein.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dedication: This manuscript is dedicated to the memory of the late Karen Russo, Ph.D. (United States Pharmacopeial Convention)
Rights and permissions
About this article
Cite this article
Alsante, K.M., Huynh-Ba, K.C., Baertschi, S.W. et al. Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 2: Safety Considerations of Impurities in Pharmaceutical Products and Surveying the Impurity Landscape. AAPS PharmSciTech 15, 237–251 (2014). https://doi.org/10.1208/s12249-013-0061-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-013-0061-z